PH12018502020A1 - Methods for treating and preventing c. difficile infection - Google Patents

Methods for treating and preventing c. difficile infection

Info

Publication number
PH12018502020A1
PH12018502020A1 PH12018502020A PH12018502020A PH12018502020A1 PH 12018502020 A1 PH12018502020 A1 PH 12018502020A1 PH 12018502020 A PH12018502020 A PH 12018502020A PH 12018502020 A PH12018502020 A PH 12018502020A PH 12018502020 A1 PH12018502020 A1 PH 12018502020A1
Authority
PH
Philippines
Prior art keywords
treating
preventing
methods
difficile infection
difficile
Prior art date
Application number
PH12018502020A
Other languages
English (en)
Inventor
S Ken Tanaka
Michael P Draper
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of PH12018502020A1 publication Critical patent/PH12018502020A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PH12018502020A 2016-03-24 2018-09-21 Methods for treating and preventing c. difficile infection PH12018502020A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US201662320053P 2016-04-08 2016-04-08
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Publications (1)

Publication Number Publication Date
PH12018502020A1 true PH12018502020A1 (en) 2019-07-15

Family

ID=59900751

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502020A PH12018502020A1 (en) 2016-03-24 2018-09-21 Methods for treating and preventing c. difficile infection

Country Status (13)

Country Link
US (3) US20170319603A1 (enExample)
EP (1) EP3432891A4 (enExample)
JP (3) JP7458706B2 (enExample)
CN (2) CN119454720A (enExample)
AU (3) AU2017238644B2 (enExample)
BR (2) BR122024000249A2 (enExample)
CA (1) CA3018872A1 (enExample)
MX (2) MX2018011413A (enExample)
MY (1) MY197627A (enExample)
PH (1) PH12018502020A1 (enExample)
RU (1) RU2751509C1 (enExample)
SG (2) SG10201913559VA (enExample)
WO (1) WO2017165729A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119454720A (zh) * 2016-03-24 2025-02-18 帕拉特克Spv2有限责任公司 用于治疗和预防艰难梭菌感染的方法
TWI746610B (zh) * 2016-08-03 2021-11-21 美商派瑞泰Ｓｐｖ２有限公司 9-胺甲基米諾四環素化合物及其用途
SG11201903846TA (en) * 2016-11-01 2019-05-30 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
WO2020051151A1 (en) * 2018-09-04 2020-03-12 Paratek Pharmaceuticals, Inc. Methods of treating mycobacterial infections using tetracycline compounds
CN112823014A (zh) * 2018-10-10 2021-05-18 营养株式会社 艰难梭菌感染的预防和/或治疗剂
US20230357135A1 (en) * 2020-06-11 2023-11-09 Paratek Pharmaceuticals, Inc. Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206300A (pt) * 1991-07-24 1994-08-02 Procter & Gamble Processos e composições de tratamento antimicrobiano
CZ2003344A3 (cs) * 2000-07-07 2003-05-14 Trustees Of Tufts College 9-Substituované minocyklinové sloučeniny
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP1408987B1 (en) * 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
WO2007075792A1 (en) * 2005-12-22 2007-07-05 Wyeth Methods of treating gastrointestinal tract infections with tigecycline
EP1991236A2 (en) * 2006-01-24 2008-11-19 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
EP2144870A2 (en) 2007-04-27 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
TWI585071B (zh) * 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
US20110294726A1 (en) * 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
AU2011239470B2 (en) * 2010-04-15 2015-09-10 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
MX369877B (es) * 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
CN119454720A (zh) * 2016-03-24 2025-02-18 帕拉特克Spv2有限责任公司 用于治疗和预防艰难梭菌感染的方法

Also Published As

Publication number Publication date
EP3432891A1 (en) 2019-01-30
MY197627A (en) 2023-06-29
CN109152789A (zh) 2019-01-04
EP3432891A4 (en) 2019-10-30
CA3018872A1 (en) 2017-09-28
MX2018011413A (es) 2019-01-10
MX2023004969A (es) 2023-05-24
RU2751509C1 (ru) 2021-07-14
JP2022115985A (ja) 2022-08-09
BR122024000249A2 (pt) 2024-02-27
JP7458706B2 (ja) 2024-04-01
CN119454720A (zh) 2025-02-18
JP2019509318A (ja) 2019-04-04
SG10201913559VA (en) 2020-02-27
JP2024023187A (ja) 2024-02-21
AU2017238644A1 (en) 2018-10-25
AU2017238644B2 (en) 2022-12-15
AU2023200798A1 (en) 2023-03-09
SG11201808246SA (en) 2018-10-30
US20250049819A1 (en) 2025-02-13
US20170319603A1 (en) 2017-11-09
BR112018069303A2 (pt) 2019-01-22
WO2017165729A1 (en) 2017-09-28
AU2025202020A1 (en) 2025-04-10
US20200281948A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
MX2023004969A (es) Metodos para tratar y prevenir infeccion por c. difficile.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
GB2541571A (en) Pharmaceutical compositions
MX2021010418A (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
MY184870A (en) Immunomodulators
WO2015117081A3 (en) Methods and compositions for treatment of a beta thalessemia
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX379622B (es) Compuestos espirociclicos
TW201613587A (en) Medical treatments based on anamorelin
PH12017500602A1 (en) Methods for treating ocular conditions
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
IL252197A0 (en) A method for treating, preventing or reducing the risk of skin infection
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020007742A (es) Procesos para preparar fluorocetolidos.
HK1255221A1 (zh) 使用卡多曲组合物进行治疗的方法
GB201708792D0 (en) Plant treatment composition
EP3283103A4 (en) Methods for treating clostridium difficile infection and associated disease
EP3448377A4 (en) METHODS FOR THE TREATMENT OF AN INFECTION